

WHO WE ARE

MarkPap Pacific LLC has acquired exclusive license for commercialization of BioSciCon's MarkPap® technology products and services on the Greater Pacific Area markets.

The LLC is offering for licensing/leasing/sale the following three products/services:

(1) **Home Specimen Sampling Kit** to address women who do not participate in cancer screening, mostly rural China (2) **Reagent Kits** with Instructions for specimen processing and Quality Control Procedures to enable small labs and low-trained persons to standardize the diagnostic procedures, and (3) **Distant Diagnosis -- telemedicine-based diagnostic services** to connect remote points-of-care with medical centers with high quality services. All these makes MarkPap ® platform technology low-cost, simple, accurate, accessible, infrastructure independent and equitable for women regardless where they live. However, the success could be achieved only if the Strategy is applied completely in its entirety.

WHERE WE ARE

JOHNS HOPKINS UNIVERSITY
MONTGOMERY CAMPUS



Ph 1.301.610.9130
Fx 1.301.610.7662

9605 Medical Center
Drive
Rockville, MD 20850

www.bioscicon.com

©BioSciCon, 2013

MARKPAP
PACIFIC, LLC
ROCKVILLE,
MARYLAND,
U.S.A.



To the People's Republic of China, MarkPap Pacific is offering tools (products and services) which can be used to implement a new Strategy for fighting cervical cancer with main goal to reverse the negative trends of currently increasing cervical cancer prevalence and mortality and reach the standards of developed countries faster and for lower cost than it is currently possible.

02

HOW WE CAN HELP




China has 1.3 bn population with 0.4 bn women at risk for cervical cancer. In 2010, 75,000 women were diagnosed with cervical cancer and 35,000 died. Prognosis was that by 2025, this number will increase with a rate of 10% per annum. This trend can be reversed with the New Strategy implementing our tools.

WHAT IS THE STRATEGY FOR HEALTH PROTECTION IN CHINA

Cervical cancer is the major killer of women from malignant diseases in developing world. However, it is preventable and curable IF detected on time. PR of China has a Health Care System suited for preventive medicine. Under this System the Central Government may plan, design, and execute the best preventive measures. This happened with cervical cancer screening, where from single digit the outreach was raised to about 25%. It is 80% in USA. BioSciCon's MarkPap® novel products and services, when implemented will help to reach faster the standards of developed countries. One product, the Reagent Kit is already in China and is selling under the name of FSC-811 by Anhui Hefei Anyon Biopharmaceuticals.

WHAT IS THE BENEFIT



However, all three products and the New Strategy are necessary in order to successfully achieve its social impact (saving ten of thousands women's lives) and commercial benefit, financial impact for all. Education is also very important.

BioSciCon's MarkPap® Technology is a combination of cytopathology, M-telemedicine and home testing

